There was one fly in the ointment, though. Interim results announced in July from a phase 3 study of Revlimid in treatingdiffuse large B-cell lymphoma (DLBCL) were disappointing. While the results showed significant improvement for patients taking Revlimid in progression-free survival, no benefit was seen in overall survival. Celgene ended up abandoning plans to seek approval for the DLBCL indication.